Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 6/20 | 0.35 |
| ▸ | FEN1 | P39748 | 6/20 | 0.35 |
| ▸ | NAAA | Q02083 | 2/20 | 0.33 |
| ▸ | FPR2 | P25090 | 2/20 | 0.32 |
| ▸ | CHKA | P35790 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.30 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12822418 | 1.00 | FFAR4 (0.35) | FFAR4ALOX5APFEN1NAAAFPR2 | |
| SCHEMBL12823248 | 0.92 | FFAR4 (0.35) | FFAR4ALOX5APFEN1NAAAFPR2 | |
| SCHEMBL12823720 | 0.92 | FFAR4 (0.35) | FFAR4ALOX5APFEN1NAAAFPR2 | |
| SCHEMBL12739956 | 0.90 | FFAR4 (0.36) | FFAR4ALOX5APFEN1FPR2CHKA | |
| SCHEMBL12735280 | 0.90 | FFAR4 (0.36) | FFAR4ALOX5APFEN1FPR2CHKA | |
| SCHEMBL12739945 | 0.90 | FFAR4 (0.35) | FFAR4ALOX5APFEN1NAAAFPR2 | |
| SCHEMBL12735259 | 0.90 | FFAR4 (0.35) | FFAR4ALOX5APFEN1NAAAFPR2 | |
| SCHEMBL12719192 | 0.88 | FFAR4 (0.33) | FFAR4ALOX5APFEN1CHKA | |
| SCHEMBL13586610 | 0.88 | FFAR4 (0.35) | FFAR4ALOX5APFEN1CHKA | |
| SCHEMBL13586310 | 0.88 | FFAR4 (0.33) | FFAR4ALOX5APFEN1CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| WO-2009150966-A1 | TETRACYCLIC LIQUID CRYSTALLINE COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | チッソ株式会社 (JP) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | FFAR4 546/4885ALOX5AP 1673/4885FEN1 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.